The results of the GSEA enrichment analysis are shown in Figure 7C. This result suggests that CHRNA9 may participate in the progression of glioma disease by interfering with wp cytokines and inflammatory response (NES =1.80, P = 0.02), ECM receptor interaction (NES =1.74, P = 0.02), extracellular matrix organization (NES =1.71, P = 0.02), cytokine receptor interaction (NES =1.71, P = 0.02), and JAK STAT signaling pathway (NES =1.44, P = 0.04). The gene discussed is CHRNA9; the disease is central nervous system cancer.